Abstract
BackgroundBoth ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2 ADCs...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have